Bioconjugates (ADC) & antibody clinical & commercial manufacturing.

The company is a wholly owned subsidiary of a global leading Contract Development and Manufacturing Organization (CDMO) with over 27-year experience for small molecules, peptides and biologics. We are a large US FDA-inspected CDMO, renowned for our expertise in developing sustainable processes from early-stage, late-phase to commercial drug products.
The state-of-the-art Jinshan facility focus on providing biologics CDMO services. It is located in Shanghai and is situated 50 KM south of the Hongqiao International Airport. The facility was established in 2019 and was certified by EU QP audit in 2024. Additionally, the facility has passed 50+ client audits, including 5+ audits from MNCs.
For antibodies, our team in Jinshan adopts phase-appropriate approach to drive efficient, scalable, and cost-effective cell line development, upstream and downstream process development, analytical development and DP development. GMP manufacturing of DS and DP can meet the needs of global clients with 200L-2,000 L bioreactors, ORABS-based DP line and 5 m² freeze dryer.
For bioconjugates, the Jinshan facility is the essential part of our all-in-one solutions. Conjugation toolbox offers customized solutions based on our keen scientific understanding of cutting-edge bioconjugation technologies. Working closely with payload-linker site in Tianjin, well-established OEB-5 workshop can address clinical and commercial DS and DP demands with 50L-500L conjugation reactors, isolator-based filling system, 5 m² and 10 m² freeze dryers.